Aim: To assess the 104‐week efficacy and safety of sitagliptin and metformin as initial
combination therapy and as monotherapy in patients with type 2 diabetes and inadequate …

MAN)—Incretin mimetics and inhibitors of the protease dipeptidyl peptidase (DPP)-4 are
new classes of antidiabetic agents first introduced in the years 2005 (exenatide) and 2007 …

Aims: To evaluate the efficacy and safety of initial combination therapy with linagliptin plus
metformin versus linagliptin or metformin monotherapy in patients with type 2 diabetes …

Aims: To investigate the safety, tolerability, pharmacokinetic and pharmacodynamic
properties of multiple oral doses of the dipeptidyl peptidase‐4 (DPP‐4) inhibitor linagliptin …

Aims: To compare the incidence of symptomatic hypoglycaemia in fasting Muslim patients
with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan. Methods …

Mitogen-activated protein kinases (MAPKs) and nuclear factor (NF)-ĸB signaling have been
recognized for their causal connection with liver fibrosis. Hence, it is encouraging to discover …

Type 2 diabetes mellitus traditionally has been characterized by insulin resistance and β‐
cell dysfunction, leading to hyperglycemia and eventual micro‐and macrovascular …

Objective: To assess the 54-week efficacy and safety of initial combination therapy with
sitagliptin and metformin in patients with type 2 diabetes and inadequate glycemic control …

Oral therapy for type 2 diabetes mellitus, when used appropriately, can safely assist patients
to achieve glycaemic targets in the short to medium term. However, the progressive nature of …

This is the second of a 2-part series focusing on newer therapies for type 2 diabetes and
their cardiovascular implications. In the first segment, we reviewed the thiazolidinediones …